ArticleFrontiers in public health2025
An analysis of the global, regional, and national burden of blindness and vision loss between 1990 and 2021: the findings of the Global Burden of Disease Study 2021.
Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Bioactive Properties of Carotenoids in Ocular Diseases: Antioxidant, Anti-Inflammatory, and Neuroprotective Effects.Nutrients · 2026Review
- Anthocyanins as Adjunctive Dietary Modulators of the Gut-Eye Axis: Bioavailability, Biotransformation, and Implications for Ocular Health.Foods (Basel, Switzerland) · 2026Review
- Brain-Computer Interfaces for Vision Recovery in Precortical Vision Loss.Eye and brain · 2026Review
- Visual Impairment and Cancer Risk: A Nationwide Cohort Study of Adult Swedish Men and Women.Cancers · 2025Article
- Burdens of sense organ diseases across global, regional, and national levels from 1990 to 2021 and projections for 2050.BMC public health · 2025Article
- Global, regional, and national burden of atrial fibrillation and flutter associated with metabolic risk factors, 1990-2021.Frontiers in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To evaluate the global burden of blindness and vision loss (BVL) from 1990 to 2021 using a retrospective analysis of epidemiological data from Global Burden of Disease (GBD) study 2021 and to project trends over the next 15 years. Methods: This retrospective study analyzed data on years lived with disability (YLDs) and prevalence across 204 countries and territories. Trends over time were assessed using estimated annual percentage change (EAPC) of the age-standardized rates (ASR), while decomposition analysis quantified the contributions of population aging, growth, and epidemiological shifts. Socioeconomic disparities were evaluated using the Slope Index of Inequality and the Concentration Index. Future trends in age-standardized prevalence rates (ASPR) and age-standardized YLDs rates (ASYR) were projected using Bayesian age-period-cohort modeling. Results: Between 1990 and 2021, global YLDs due to BVL more than doubled, increasing from 14.31 to 29.16 million. The prevalence of BVL surged by 246.8%, with a disproportionately higher burden observed among females. Regions with low to middle Socio-Demographic Index (SDI) scores exhibited the highest ASPR and ASYR. Population growth and aging were the primary drivers of the increasing burden, while epidemiological trends had mixed effects. Significant socioeconomic disparities persist, with a higher concentration of BVL burden in economically disadvantaged regions. Projections indicate a continued increase in BVL burden through 2036, particularly among women and older populations. Conclusion: Despite advancements in healthcare, the global burden of BVL has substantially increased over the past 32 years, driven by demographic and socioeconomic factors. Persistent disparities highlight the urgent need for targeted public health interventions, equitable resource allocation, and policy initiatives to address the growing impact of BVL worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.